Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04150198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY

Study acronym: PET-AL
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years later Dec 2025 → Dec 31, 2028
See other at-risk trials from Institut National de la Santé Et de la Recherche Médicale, France

Record History

  1. Notable Primary completion pushed from Dec 2025 to Dec 31, 2028
    • Study completion pushed from Dec 2026 to Dec 31, 2029
    v5
  2. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Jul 15, 2023 to Dec 2025
    • Start date changed from estimate of Apr 15, 2021 to Dec 8, 2021
    • Study completion date: Dec 15, 2023 to Dec 2026
    • Site details revised at 2 of 2 sites
  3. Notable Primary completion date: Feb 15, 2022 to Jul 15, 2023
    • Start date: Apr 1, 2020 to Apr 15, 2021
    • Study sites: 1 to 2
    • Study completion date: May 15, 2022 to Dec 15, 2023
    v3
  4. Notable Start date: Nov 15, 2019 to Apr 1, 2020v2
  5. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with Alzheimer's disease and with early onset of symptoms (\<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground. In addition, some MA-J have an atypical phenotype indicating focal brain damage, although they have the same pathological lesions: amyloid deposits and tau protein deposition (DNF). This is the case of posterior cortical atrophy (PCA) characterized by complex visual disturbances and atrophy affecting the more posterior regions of the brain. Based on the clinical profile of PCA patients, a more refined anatomo-clinical classification was proposed, distinguishing a rather "ventral" form and a rather "dorsal" form. The recent arrival of tau-specific PET tracers now makes it possible to evaluate in vivo fibrillary neurodegeneration (FND), which is well correlated with the severity of cognitive disorders. Advances in MRI have shown that each neurodegenerative syndrome targets a large-scale neural network, which in turn shows a vulnerability for a specific biological disease. In the case of AD, the reason for such a difference in cognitive and anatomical impairment between patients with diffuse involvement and others with more focal involvement is not known. One possible explanation is the existence, in focal forms, of neuronal mechanisms that oppose vulnerability. These mechanisms may correspond to the so-called "resilience" phenomenon, defined as resistance to a neuropathological process by the ability to optimize cognitive performance via the efficient recruitment of neural networks. The mechanisms underlying resilience in neurodegeneration are unknown. Their identification is very important for the management and treatment of AD.
Trial Details
NCT Number NCT04150198
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Collaborators: France Alzheimer
Conditions
(from sponsor)
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
Related terms Alzheimer Disease
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov